While the company is advancing its clinical pipeline with multiple trials and strategic collaborations, the significant cash burn and declining reserves pose near-term execution risks. Traders should monitor upcoming milestones, including IND submission in Malaysia by June 2026 and completion of the Singapore CAR-T trial, as well as any potential financing activities given the reduced cash balance.
Price Chart
Executive Summary
CytoMed Therapeutics reported full-year 2025 financial results with revenue growth to $780,857 but a wider net loss of $3.11 million, up from $1.96 million in 2024, driven by increased R&D and employee expenses. The company highlighted clinical progress in its CAR-T and unmodified gamma delta T cell programs, including a new MOU with Universiti Malaya for a Phase I trial in Malaysia and co-publication with MD Anderson on AML potential. Cash reserves declined to $1.63 million from $3.87 million, raising near-term liquidity concerns despite claims of sufficient funding.
Key Facts
- Total revenue increased to $780,857 in 2025 from $663,786 in 2024
- Audited net loss widened to $3.11 million in 2025 from $1.96 million in 2024
- Cash and bank balances declined to $1.63 million as of December 31, 2025, from $3.87 million a year earlier
- Research expenses rose to $1.72 million in 2025 from $1.48 million in 2024
- Employee benefits expenses increased to $723,667 in 2025 from $481,629 in 2024, including $240,491 in share-based compensation
- First-in-human ANGELICA CAR-T Phase I trial in Singapore is progressing to dose level 3, with completion targeted in 2026
- Memorandum of Understanding signed with Universiti Malaya to launch a Phase I trial for unmodified gamma delta T cells in Malaysia
- Co-authored preclinical study with MD Anderson suggests potential of CTM-GDT therapy for acute myeloid leukemia (AML)
- Acquired assets of a Malaysian cord blood bank, including a private blood bank license, through subsidiary IPSC Depository Sdn. Bhd.
- Made an equity investment in a Malaysian general medical clinic services provider
Financial Impact
Revenue increased 17.6% YoY to $780,857, but net loss expanded by 58.7% to $3.11 million. Cash burn was $2.24 million in 2025, with cash reserves now at $1.63 million.
Risk Factors
- High cash burn rate and declining cash reserves may necessitate near-term dilutive financing
- Clinical trial delays or adverse safety signals could impact development timelines
- Reliance on co-funding and partnerships introduces execution and dependency risk
- Small market cap ($12M) increases volatility and susceptibility to sentiment shifts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-013882 |
| Document: 0001493152-26-013882-index-headers.html | 0001493152-26-013882 |
| Document: 0001493152-26-013882-index.html | 0001493152-26-013882 |
| Document: 0001493152-26-013882.txt | 0001493152-26-013882 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | SC 13G/A | $0.9190 $0.9262 | ▲ +0.78% | ▲ +0.07% | $0.9262 (+0.78%) |
Oct 16, 2026 10d ago | SC 13D/A | $0.8799 $0.8520 | ▼ −3.17% | ▼ −3.59% | $0.9262 (+5.26%) |
Oct 13, 2026 13d ago | SC 13D/A | $0.8700 $0.8599 | ▼ −1.16% | ▼ −0.08% | $0.9262 (+6.46%) |
Oct 9, 2026 16d ago | 6-K | $0.8114 $0.8700 | ▼ −7.22% | ▼ −7.23% | $0.9262 (−14.15%) |
Sep 30, 2026 26d ago | 6-K | $0.8430 $0.8999 | ▼ −6.75% | ▼ −6.57% | $0.9262 (−9.87%) |
May 15, 2026 23w ago | 6-K | $1.16 $1.21 | ▲ +4.31% | ▲ +4.37% | $0.9262 (−20.16%) |
May 11, 2026 24w ago | 6-K | $0.8090 $0.7690 | ▼ −4.94% | ▼ −4.81% | $0.9262 (+14.49%) |
Mar 31, 2026 29w ago | 6-K | $1.00 $1.03 | ▲ +3.00% | ▲ +2.25% | $0.9262 (−7.38%) |
Mar 31, 2026 29w ago | 20-F | $1.00 $1.03 | ▲ +3.00% | ▲ +2.25% | $0.9262 (−7.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers